An official website of the United States government
Home
Name
Bemcentinib
Alternate Names
BGB324
R428
Abbreviations
None
Category
Chemotherapy
Subcategory
AXL inhibitor
NSC Number
None
Primary Site
None
Histology
Myeloid leukemia
Remarks
10/25/2019
FDA has approved Fast Track designation for bemcentinib for treatment of elderly patients with acute myeloid leukemia (AML) whose disease has relapsed. CODE IN OTHER TREATMENT DATA FIELD UNTIL FINAL APPROVAL BY FDA
FDA has approved Fast Track designation for bemcentinib for treatment of elderly patients with acute myeloid leukemia (AML) whose disease has relapsed. CODE IN OTHER TREATMENT DATA FIELD UNTIL FINAL APPROVAL BY FDA
Coding
Please see remarks for additional information
